Sensitisation Clinical Trial
Official title:
Non-Randomized, Single-Center Pilot Trial Assessing The Safety/Efficacy Of Targeting Peripheral And Central Humoral Alloimmune Memory With Daratumumab And With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
While the number of kidney transplants is increasing worldwide every year, there is a clear imbalance between the high number of patients in the waiting list and those receiving a transplant and importantly, among waitlist patients there is a progressively higher number of highly sensitised patients that have very low or even no chance to receive a compatible organ. These patients remain for very long periods of time on dialysis therapy, having lower quality of life, lower life expectancy and produce higher health-related costs. Unfortunately, current desensitization therapies have shown very poor success and patients usually lose these grafts very fast if transplanted across a positive cross-match. Therefore, there is an urgent need for novel desensitization strategies capable of overcoming this immunological barrier and allow an increasing number of patients to receive a HLA-compatible kidney allograft.This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA or TGI ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for >3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial.
This is a non-randomized, single arm study, combination trial designed according to the Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. The study will enroll 12 patients with cPRA or TGI ≥99% on the deceased donor kidney transplant waiting list, who have not received a compatible donor offer for >3 year. According to inclusion and exclusion criteria patients will be screened to participate in the trial. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT04818190 -
DIEP (Deep Inferior Epigastric Artery Perforator) Flap Sensory Recovery Following Neurotization
|
N/A | |
Completed |
NCT05079607 -
Human Skin Safety Testing of a Mitopure Topical Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Volunteers
|
N/A | |
Recruiting |
NCT06204510 -
Effects of Complex Decongestive Therapy on Proprioception, Balance and Tactile Sense
|
N/A | |
Completed |
NCT06047704 -
The Effect of State and Trait Anxiety on Pain-pressure Threshold
|
||
Enrolling by invitation |
NCT01473823 -
Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood
|
N/A | |
Completed |
NCT04498676 -
50 Human Subject Repeat Insult Patch Test
|
N/A | |
Recruiting |
NCT03223844 -
Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release
|
N/A | |
Not yet recruiting |
NCT05704218 -
Hypersensitivity Pneumonitis of Domestic Origin
|
N/A | |
Completed |
NCT04510675 -
Irritation Potential of Omeza Collagen Matrix Using Modified HRIPT
|
N/A |